Clinical significance of the FIB-4 index for non-B non-C hepatocellular carcinoma treated with surgical resection

Oncology Reports

Volumn 33, Issue 1, 2015, Pages 88-94

  Nishikawa, Hiroki ^a   Osaki, Yukio ^a   Komekado, Hideyuki ^a   Sakamoto, Azusa ^a   Saito, Sumio ^a   Nishijima, Norihiro ^a   Nasu, Akihiro ^a   Arimoto, Akira ^a   Kita, Ryuichi ^a   Kimura, Toru ^a  

^a OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

FIB 4 index; Liver fibrosis; Non B non Chepatocellular carcinoma; Overall survival; Recurrence free survival

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER SURGERY; CONTROLLED STUDY; FEMALE; FIB4 INDEX; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NON B NON C HEPATOCELLULAR CARCINOMA; OVERALL SURVIVAL; PREDICTOR VARIABLE; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; AREA UNDER THE CURVE; CARCINOMA, HEPATOCELLULAR; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LIVER NEOPLASMS; LIVER RESECTION; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AGED; ALANINE TRANSAMINASE; AREA UNDER CURVE; ASPARTATE AMINOTRANSFERASES; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PLATELET COUNT; RETROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84916219647     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3573     Document Type: Article

References (38)

1. Osaki Y and Nishikawa H: Treatment for hepatocellular carcinoma in Japan over the last three decades: our experience and published work review. Hepatol Res: Jun 26, 2014 (Epub ahead of print). doi: 10.1111/hepr.12378.
2. El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142: 1264-1273, 2012.
3. de Lope CR, Tremosini S, Forner A, Reig M and Bruix J: Management of HCC. J Hepatol 56 (Suppl 1): S75-S87, 2012.
4. Kaibori M, Ishizaki M, Matsui K and Kwon AH: Clinicopathologic characteristics of patients with non-B non-C hepatitis virus hepatocellular carcinoma after hepatectomy. Am J Surg 204: 300-307, 2012.
5. Nishikawa H and Osaki Y: Non-B, non-C hepatocellular carcinoma (Review). Int J Oncol 43: 1333-1342, 2013.
6. Utsunomiya T and Shimada M: Molecular characteristics of noncancerous liver tissue in non-B non-C hepatocellular carcinoma. Hepatol Res 41: 711-721, 2011.
7. Umemura T and Kiyosawa K: Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res 37 (Suppl 2): S95-S100, 2007.
8. Zhou WP, Lai EC, Li AJ, Fu SY, Zhou JP, Pan ZY, Lau WY and Wu MC: A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg 249: 195-202, 2009.
9. Nishikawa H, Osaki Y, Kita R, Kimura T, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S, Hatamaru K, Saito S and Nasu A: Transcatheter arterial infusion chemotherapy prior to radiofrequency thermal ablation for single hepatocellular carcinoma reduces the risk of intrahepatic distant recurrence. Int J Oncol 41: 903-909, 2012.
10. Nishikawa H, Osaki Y, Kita R, Kimura T, Ohara Y, Takeda H, Sakamoto A, Saito S, Nishijima N, Nasu A, Komekado H and Nishiguchi S: Comparison of transcatheter arterial chemoembolization and transcatheter arterial chemotherapy infusion for patients with intermediate-stage hepatocellular carcinoma. Oncol Rep 31: 65-72, 2014.
11. Castera L: Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. Best Pract Res Clin Gastroenterol 25: 291-303, 2011.
12. Chrostek L and Panasiuk A: Liver fibrosis markers in alcoholic liver disease. World J Gastroenterol 20: 8018-8023, 2014.
13. Sumida Y, Nakajima A and Itoh Y: Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 20: 475-485, 2014.
14. Smith JO and Sterling RK: Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther 30: 557-576, 2009.
15. D 'Onofrio M, Crosara S, De Robertis R, Canestrini S, Demozzi E, Gallotti A and Pozzi Mucelli R: Acoustic radiation force impulse of the liver. World J Gastroenterol 19: 4841-4849, 2013.
16. M ariappan YK, Glaser KJ and Ehman RL: Magnetic resonance elastography: a review. Clin Anat 23: 497-511, 2010.
17. Yu ML, Lin SM, Lee CM, Dai CY, Chang WY, Chen SC, Lee LP, Lin ZY, Hsieh MY, Wang LY, Chuang WL and Liaw YF: A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology 44: 1086-1097, 2006.
18. Castera L: Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 142: 1293-1302, 2012.
19. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H and Pol S: FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 46: 32-36, 2007.
20. Angulo P, Bugianesi E, Bjornsson ES, P, Mills PR, Barrera F, Haflidadottir S, Day CP and George J: Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 145: 782-789.e4, 2013.
21. Tamaki N, Kurosaki M, Matsuda S, Muraoka M, Yasui Y, Suzuki S, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Asahina Y and Izumi N: Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients. J Gastroenterol: Dec 15, 2013 (Epub ahead of print).
22. Chon YE, Jung ES, Park JY, Kim do Y, Ahn SH, Han KH, Chon CY, Jung KS and Kim SU: The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B. J Clin Gastroenterol 46: 518-525, 2012.
23. Shen SL, Fu SJ, Chen B, Kuang M, Li SQ, Hua YP, Liang LJ, Guo P, Hao Y and Peng BG: Preoperative aspartate aminotransferase to platelet ratio is an independent prognostic factor for hepatitis B-induced hepatocellular carcinoma after hepatic resection. Ann Surg Oncol: May 22, 2014 (Epub ahead of print).
24. Hung HH, Su CW, Lai CR, Chau GY, Chan CC, Huang YH, Huo TI, Lee PC, Kao WY, Lee SD and Wu JC: Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma. Hepatol Int 4: 691-699, 2010.
25. Alberti KG and Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553, 1998.
26. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS and Lok AS: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38: 518-526, 2003.
27. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M; APRICOT Clinical Investigators: Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43: 1317-1325, 2006.
28. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 42: 1208-1236, 2005.
29. No authors listed: The general rules for the clinical and pathological study of primary liver cancer. Liver Cancer Study Group of Japan. Jpn J Surg 19: 98-129, 1989.
30. Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Takayama T and Kokudo N; for the Liver Cancer Study Group of Japan: A Comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients. Ann Surg: Jul 28, 2014 (Epub ahead of print).
31. Nalbantoglu I and Brunt EM: Role of liver biopsy in nonalcoholic fatty liver disease. World J Gastroenterol 20: 9026-9037, 2014.
32. Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, Li G and Wang L: Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer 130: 1639-1648, 2012.
33. Calle EE, Rodriguez C, Walker-Thurmond K and Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348: 1625-1638, 2003.
34. Nishikawa H and Osaki Y: Clinical significance of therapy using branched-chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma. Hepatol Res 44: 149-158, 2014.
35. Jung KS, Kim SU, Choi GH, Park JY, Park YN, Kim do Y, Ahn SH, Chon CY, Kim KS, Choi EH, Choi JS and Han KH: Prediction of recurrence after curative resection of hepatocellular carcinoma using liver stiffness measurement (FibroScan®). Ann Surg Oncol 19: 4278-4286, 2012.
36. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S and Makuuchi M: Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38: 200-207, 2003.
37. M cCurry J: Japan battles with obesity. Lancet 369: 451-452, 2007.
38. Examination Committee of Criteria for 'Obesity Disease' in Japan; Japan Society for the Study of Obesity: New criteria for 'Obesity Disease' in Japan. Circ J 66: 987-992, 2002.